Back to Directory Chris Rupert Email rupert@frontierscience.org Phone 716-834-0900 x7442 Institution Frontier Science Foundation Address Frontier Science Foundation 4033 Maple Road Amherst, NY 14226 USA Request an Update Affiliated Studies IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy Study Status In Development P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants DAIDS Number 11882 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2049: LEAP DAIDS Number TBA Research Area Tuberculosis Study Status In Development IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Accrual Show All
IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy Study Status In Development
P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants DAIDS Number 11882 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Accrual